Surmodics, Inc. - Common Stock (NQ:SRDX)

42.98 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

April 03, 2025

From Surmodics, Inc.

Via Business Wire

Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private ↗

March 07, 2025

This week's Deal Dispatch has updates on Raizen, Walgreens, TikTok and Canoo. Plus: the FTC is blocking mergers like it's 2017 again.

Via Benzinga

Why Surmodics Stock Is Falling On Friday ↗

March 07, 2025

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

Via Benzinga

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

March 06, 2025

From Surmodics, Inc.

Via Business Wire

Top 3 Health Care Stocks You'll Regret Missing This Month ↗

February 06, 2025

Via Benzinga

Surmodics Earnings Analysis: Q1 Recap ↗

January 30, 2025

Via Benzinga

Assessing Surmodics: Insights From 5 Financial Analysts ↗

May 30, 2024

Via Benzinga

Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

February 03, 2025

From Surmodics, Inc.

Via Business Wire

Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

January 30, 2025

From Surmodics, Inc.

Via Business Wire

Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

November 06, 2024

From Surmodics, Inc.

Via Business Wire

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

October 30, 2024

From Surmodics, Inc.

Via Business Wire

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

October 01, 2024

From Surmodics, Inc.

Via Business Wire

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024 ↗

July 31, 2024

SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.

Via InvestorPlace

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

July 31, 2024

From Surmodics, Inc.

Via Business Wire

SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

July 17, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders

July 08, 2024

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders

July 04, 2024

From Halper Sadeh LLC

Via GlobeNewswire

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

June 10, 2024

From Surmodics, Inc.

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)

June 06, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

May 30, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 29, 2024

Via Benzinga

Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals ↗

May 29, 2024

Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal.

Via Investor's Business Daily

Why Is Medical Coating Specialist Surmodics Trading Higher On Wednesday? ↗

May 29, 2024

Surmodics will be acquired by GTCR for $43.00 per share, totaling $627 million. This 41.1% premium reflects Surmodics' advancements in surface modification for medical devices and IVD technologies.

Via Benzinga

Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday ↗

May 29, 2024

Via Benzinga

SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders

May 29, 2024

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 29, 2024

Via Benzinga

Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million

May 29, 2024

From Surmodics, Inc.

Via Business Wire

Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 01, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 01, 2024

Via Benzinga

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024 ↗

May 01, 2024

SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.